• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Top 3 Hep C Studies for Primary Care

Slideshow

Highlights of 3 studies from 2017 that support the role of PCPs in HCV infection treatment, including prescribing direct-acting antiviral agents.

Three recent studies show the value of using direct-acting antiviral (DAA) agents to treat patients infected with hepatitis C virus (HCV), including treatment by primary care physicians: The majority of patients infected with HCV can be safely, effectively managed in a primary care setting.HCV viral load after four weeks of treatment with DAAs predicts sustained virologic response (SVR) in a real-world clinical setting.DAA therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney disease 

© 2024 MJH Life Sciences

All rights reserved.